

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claim 1 (currently amended): An isolated antibody comprising an immunoglobulin heavy chain (HC) variable domain and an immunoglobulin light chain (LC) variable domain, wherein the HC variable domain and the LC variable domain form an antigen binding site that binds to an activated conformation of LFA-1, wherein the antibody comprises has one or more of the following properties:

- (i) the a heavy chain variable domain that comprises (a) a CDR1 that comprises RYVMW (SEQ ID NO:1); (b) a CDR2 that comprises YIWPSGGNTYYADSVKG (SEQ ID NO:2); and (c) a CDR3 that comprises a sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:56 and SEQ ID NO:57 X_a-S-X2-D-X4-X5-S-X7-A-X8-X9-X10-X11 (SEQ ID NO:4), and X_a is S or N; X2 is Y or F; X4 is hydrophobic; X5 is W or R; X7 is N or Y; X9 is Y or F; X10 is D, E or A; and X11 is any amino acid; and (ii) the a light chain variable domain that comprises (d) (a) a CDR1 that comprises RASQSIGSYLN (SEQ ID NO:7); (b) (c) a CDR2 that comprises AASSLQS (SEQ ID NO:8); and (e) (f) a CDR3 that comprises QQSYSTPS (SEQ ID NO:9); or
 - (ii) (iii) the a heavy chain variable domain that comprises SEQ ID NO:23, SEQ ID NO:25, SEQ ID NO:27, or SEQ ID NO:29; and (iv) the a light chain variable domain that comprises SEQ ID NO:22, SEQ ID NO:24, SEQ ID NO:26, or SEQ ID NO:28; or
 - (iii) (v) the a heavy chain variable domain that comprises a sequence encoded by a nucleic acid that hybridizes under high stringent conditions to the complement of the full length of SEQ ID NO:42, SEQ ID NO:43, or SEQ ID NO:44; and (vi) the a light chain variable domain that comprises a sequence encoded by a nucleic acid that hybridizes under high stringent conditions to the complement of the full length of SEQ ID NO:39, SEQ ID NO:40, or SEQ ID NO:41; or
 - (iv) an antibody selected from the group consisting of
 - a) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:23, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:22;
 - b) an immunoglobulin heavy chain variable domain sequence comprising

SEQ ID NO:25, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:24;

c) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:27, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:26; and

d) an immunoglobulin heavy chain variable domain sequence comprising SEQ ID NO:29, and an immunoglobulin light chain variable domain sequence comprising SEQ ID NO:28;

for binding to activated LFA-1.

Claim 2 (previously presented): The antibody of claim 1 that comprises the CDR regions of (i) and (ii).

Claim 3 (previously presented): The antibody of claim 1 wherein the heavy and light chain variable domain sequences comprise, respectively, SEQ ID NO:23 and SEQ ID NO:22.

Claim 4 (currently amended): The antibody of claim 1 wherein at least the protein framework regions are identical to the framework regions of SEQ ID NO:33 (light chain) and SEQ ID NO:36 (heavy chain); SEQ ID NO:34 (light chain) and SEQ ID NO:37 (heavy chain); or SEQ ID NO:35 (light chain) and SEQ ID NO:38 (heavy chain).

Claim 5 (previously presented): The antibody of claim 1 wherein the CDR3 of the heavy chain variable domain comprises SYDFWSNAFDI (SEQ ID NO:3).

Claim 6 (previously presented): The antibody of claim 1 that is not immunogenic in humans.

Claim 7 (previously presented): The antibody of claim 1 that is a full length IgG antibody.

Claim 8 (previously presented): The antibody of claim 1 that is an antigen binding fragment of an antibody, and does not include an Fc domain.

Claim 9 (previously presented): The antibody claim 1 that has at least a 20-fold preference for binding to activated LFA-1 relative to inactivated LFA-1.

Claim 10 (canceled)

Claim 11 (previously presented): A pharmaceutical composition that comprises the antibody according to any of claims 1-10 and a pharmaceutically acceptable salt.

Claims 12-33 (canceled)

Claim 34 (previously presented): The antibody of claim 1 wherein the heavy and light chain variable domain sequences comprise, respectively, SEQ ID NO:60 and SEQ ID NO:61.

Claim 35 (previously presented): The antibody of claim 1 comprising SEQ ID NO:33 (light chain) and SEQ ID NO:36 (heavy chain); SEQ ID NO:34 (light chain) and SEQ ID NO:37 (heavy chain); or SEQ ID NO:35 (light chain) and SEQ ID NO:38 (heavy chain).

Claim 36 (currently amended): An isolated antibody comprising an immunoglobulin heavy chain (HC) variable domain and an immunoglobulin light chain (LC) variable domain, wherein the HC variable domain and the LC variable domain form an antigen binding site that binds to an activated conformation of LFA-1, wherein the antibody comprises has one or more of the following properties: (i) the a heavy chain variable domain eomprises: comprising (a) a CDR1 that comprises HYGMS (SEQ ID NO:10); (b) a CDR2 that comprises VISPSGGRTLYADSVKG (SEQ ID NO:11); and (c) a CDR3 that comprises HYSYAMDV (SEQ ID NO:12); and (ii) the light chain variable domain comprises (a) comprising (d) a CDR1 that comprises TASQSVDSNLA (SEQ ID NO:13);

(~~b~~) (c) a CDR2 that comprises GASTRAT (SEQ ID NO:14); and (~~e~~) (f) a CDR3 that comprises QQYNKWPPYS (SEQ ID NO:15); for binding to activated LFA-1.

Claim 37 (currently amended): An isolated antibody comprising an immunoglobulin heavy chain (HC) variable domain and an immunoglobulin light chain (LC) variable domain, wherein the HC variable domain and the LC variable domain form an antigen binding site that binds to an activated conformation of LFA-1, wherein the antibody comprises has one or more of the following properties: the a heavy chain variable domain comprises: comprising (a) a CDR1 that comprises HYSMQ (SEQ ID NO:16); (b) a CDR2 that comprises VIGSSGGNTYYADSVKG (SEQ ID NO:17); and (c) a CDR3 that comprises GTYNTSPFDY (SEQ ID NO:18); and (ii) the a light chain variable domain comprises (a) comprising (d) a CDR1 that comprises SGDALGQKYAS (SEQ ID NO:19); (~~b~~) (c) a CDR2 that comprises QDSKRPS (SEQ ID NO:20); and (~~e~~) (f) a CDR3 that comprises QAWDTTAYV (SEQ ID NO:21); for binding to activated LFA-1.